This is the authors' abstract. We don't add key points for this paper.
Fifteen American patients with Burkitt's lymphoma were treated in a clinical trial employing chemotherapy, radiotherapy, and immunotherapy. Two patients died during induction, and 13 achieved complete responses. Eight patients relapsed at a median of 11 weeks from initial treatment, and seven of these have died. The remaining patient has enjoyed a prolonged third remission following intensive chemotherapy and bone marrow autograft. Five patients remain in their first remission in excess of 1 year. The major therapeutic goal in the management of Burkitt's lymphoma is the prevention of relapse; the identification of risk factors and various strategies to achieve this goal are discussed.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Ziegler et al. (1976) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: